# Treatment of IgG4-Related Disease With Revlimid and Rituximab

> **NCT02705638** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 6 (actual)

## Conditions studied

- Immunoglobulin G Subclass 4 Related Disease
- IgG4-related Disease
- Autoimmune Pancreatitis
- IgG4-related Sclerosing Cholangitis
- Retroperitoneal Fibrosis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02705638
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02705638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02705638, "Treatment of IgG4-Related Disease With Revlimid and Rituximab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02705638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*